<DOC>
	<DOCNO>NCT01664195</DOCNO>
	<brief_summary>The hypothesis trial test drug ( Eritromax ® ) pharmacokinetics pharmacodynamics parameter similar comparator drug ( Eprex ® ) healthy subject follow administration single intravenous dose . The objective randomized , crossover , clinical trial evaluate pharmacokinetic pharmacodynamic profile drug Eritromax® market Blau Farmacêutica , compare product Eprex ® , produce Janssen-Cilag , assess plasma concentration drug reticulocyte count follow single-dose intravenous administration 100 IU/kg healthy subject .</brief_summary>
	<brief_title>PK PD Study After Single Dose , Intravenous Administration Two Epoetin Alfa , Eritromax Eprex , Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Agree purpose study sign date Informed Consent ; Male , age 20 55 year , clinically healthy ; BMI 18.5 30 ; Hemoglobin 13.8 15.4 g / dL hematocrit 41 % 49 % ; VCM 82 98 , HBMC 26 34 , platelet 150,000 400,000 unit per mL . WBC 3,500 10,500 unit per ml atypical cell . Human serum ferritin 36262 mcg / L ; Counting reticulocytes peripheral blood ≤ 3 % ; Serum erythropoietin &lt; 30 mIU / mL . Participation clinical trial 12 month precede survey ; Body weight &gt; 100 kg ; Presence iron deficiency anemia ; Presence pulmonary , cardiovascular , neurological , endocrine , gastrointestinal , genitourinary system diseases ; Acute disease period 07 day begin practical phase ( administration drug ) study ; Chronic administration medication hypertension , diabetes disease require continuous use drug ; Hormone therapy period 02 month precede begin practical phase ( administration drug ) study ; Administration drug 02 week prior start practical period study ; Clinical history autoimmune hereditary anemia ; Clinical history chronic bleeding ; Clinical history acute bleed 30 day precede begin practical phase study ( administration drug ) ; Clinical history allergy biological product derive mammalian albumin component formulation ; Current previous history ( le 12 month ) illicit drug abuse / tobacco / alcohol consume alcohol within 48 hour prior practical study period ( administration drug ) ; Prior therapy erythropoietin ; Albumin 3.5 g/dL high 4.8 g/dL ; Signs clinical history bone marrow aplasia ; History clinical laboratory liver disease ; History clinical laboratory nephropathy ; Principal Investigator study criterion .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>subject</keyword>
</DOC>